In a series of notable industry updates, BioTech firm Sanofi reported positive data from phase 3 trials of its atopic dermatitis drug, and signed major license deals including a $180M upfront agreement for Kali Therapeutics' trispecific antibody. Sanofi continues to bolster its presence in T-cell engager territory with a significant $1.2B pact for phase 1-stage trispecific. Additional partnerships include a global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset and a venture with Brazil's EMS to sell generics manufacturer Medley.
Sanofi has also seen regulatory success, with EU backing for its injectable version of a blood cancer drug and the FDA granting Breakthrough Therapy designation to its Gaucher GD3 drug. Despite backing away from its plan to develop a next-generation mRNA seasonal flu vaccine, the company remains committed to innovative projects including a new innovation and operation centre in China.
However, the company has also been hit with legal troubles, with Texas filing a lawsuit against them over alleged bribery to boost drug prescriptions. The company was also recently under scrutiny over changes in leadership, specifically, the replacement of CEO Paul Hudson with outgoing Merck KGaA chief Belén Garijo.
Sanofi News Analytics from Tue, 26 Aug 2025 07:00:00 GMT to Sat, 28 Mar 2026 15:14:23 GMT - Rating 5 - Innovation 7 - Information 8 - Rumor -4
